Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial

Kooshki, Akram; Memarzadeh, Mohammad Reza; Rakhshani, Mohammad Hassan; Akbarzadeh, Roya; Tofighiyan, Tahereh; Foroumandi, Elaheh

doi:10.22038/ajp.2023.23447

Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial

Document Type : Short communication

Authors

¹ Non-Communicable Diseases Research Center, Department of Nutrition & Biochemistry, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

² Barij Medicinal Plants Research Center, Kashan, Iran

³ Department of Environmental Health, School of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁴ Department of Anesthesiology, Faculty of Paramedical, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁵ Department of Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran

10.22038/ajp.2023.23447

Abstract

Objective: This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.
Materials and Methods: Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.
Results: Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.
Conclusion: Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.

Keywords